Physician profile
Henry D Perry
NPI 1811992365
$8,811.50
in general payments reported to CMS, 2019-2025
26 companies · $2,357 in 2025
The $2,357 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $237 · 2021: $978 · 2022: $1,911 · 2023: $433 · 2024: $2,066 · 2025: $2,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,850 · Food and Beverage: $1,988 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,850.00 |
| Food and Beverage | $1,988.00 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $1,612.32 | 2024-2025 | Xdemvy |
| Kedrion Biopharma, INC. | $1,600.00 | 2025 | Rhogam Ultra-Filtered Plus, Albuked, Koate |
| Kala Pharmaceuticals, INC. | $1,200.00 | 2022 | |
| Biotissue Holdings INC. | $681.46 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $530.70 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $518.66 | 2019-2023 | Cequa, Xelpros |
| Alcon Vision LLC | $442.66 | 2019-2025 | Simbrinza, Eysuvis |
| Dompe US, INC. | $357.20 | 2019-2025 | Oxervate |
| Abbvie INC. | $261.88 | 2023-2025 | |
| Allergan, INC. | $212.62 | 2019-2021 | |
| Harrow Eye, LLC | $206.66 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $188.38 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Aerie Pharmaceuticals, INC. | $160.44 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $144.08 | 2020-2025 | Acthar |
| Glaukos Corporation | $129.74 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $118.14 | 2019 | |
| Oyster Point Pharma, INC. | $116.82 | 2022-2025 | Tyrvaya |
| Regeneron Healthcare Solutions, INC. | $102.90 | 2019 | |
| Mallinckrodt Enterprises LLC | $43.60 | 2019 | |
| Horizon Therapeutics Plc | $41.84 | 2019-2022 | |
| Eyevance Pharmaceuticals LLC | $37.38 | 2019 | |
| Thea Pharma INC. | $35.92 | 2024 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.32 | 2021 | |
| Astellas Pharma US INC | $21.51 | 2025 | Izervay |
| Ascendis Pharma Endocrinology INC | $14.20 | 2025 | Yorvipath |
| Quidel Corporation | $8.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.